$ 6 M payment to access additional cell lines

Topics: Corporate, Evotec, Celgene, IPSC, Induced pluripotent stem cells Read More

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform  

Topics: Corporate, Evotec, Drug Discovery, CENTOGENE, rare genetic diseases, IPSC Read More

$ 6 M payment to access additional cell lines

Topics: Corporate, Celgene, IPSC, Evotec Read More